LTRN Lantern Pharma Inc.

Lantern Pharma is a clinical stage biotechnology company focused on innovating the cancer drug development process by rescuing and repositioning drug candidates that others have tried, but failed, to develop and developing new drugs of its own using advanced genomics and artificial intelligence (“AI”). Lantern leverages advances in machine learning, genomics and artificial intelligence by using a proprietary AI platform to discover biomarker signatures aimed at helping identify patients more likely to respond to our pipeline of cancer therapeutics. Lantern’s focus is to improve the outcome for patients by leveraging our technology to uncover, rescue and develop abandoned or failed drugs. Lantern seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to assist with its objective of delivering cancer therapies to patients as quickly and efficiently as possible.

$15.09
As of 05/10/2021     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/11/2020
Outstanding shares:  11,181,447
Average volume:  91,563
Market cap:   $174,654,202
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    51654W101
ISIN:        US51654W1018
Sedol:      BMGLD34
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.06
PS ratio:   0.00
Return on equity:   -9.65%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy